Role of Magnetic Resonance Imaging (MRI) Perfusion to Detect Disease in Prostate Carcinoma
Status and phase
Conditions
Treatments
Details and patient eligibility
About
This is a pilot study of 50 patients to establish whether there is a potential role for MRI perfusion in the detection of locally recurrent or persistent prostate carcinoma after previous treatment with radiotherapy. All subjects will be patients who have had localised prostate cancer treated with radiotherapy and have already agreed to undergo a biopsy of the prostate to look at local control within the prostate as part of their management. The objective of the study is to establish whether there is a relationship between recurrent or persistent disease within the prostate and increased perfusion on MRI at these sites.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Previously have had radical radiotherapy for localised prostate cancer
- Due to undergo routine post-treatment prostatic biopsies
- Suitable for MRI scan
- Adequate renal function
- No previous reaction to gadolinium
- Able to give informed consent
- No recent prostate biopsy within 6 weeks of enrolment
- Performance status (Eastern Cooperative Oncology Group [ECOG]) 0 or 1
Exclusion criteria
- Not suitable for MRI scan
- Previous reaction to gadolinium
- Impaired renal function
- Inability to give informed consent
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal